Discover trends, market shifts, and competitive outlooks for the alzheimer’s drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Alzheimer’s Drugs Market In 2029?

The market size for Alzheimer’s medications has seen a marked increase over the past few years. The forecast suggests a growth from $9.33 billion in 2024 to $10.19 billion in 2025, representing a compound annual growth rate (CAGR) of 9.1%. The positive trend during the historical period is a result of an increase in the incidence of Alzheimer’s disease, major investments in research and development, a better comprehension of disease mechanisms, worldwide health initiatives, and enhanced public awareness and education.

Forecasts suggest that the Alzheimer’s drugs market is set to witness substantial expansion in the coming years, with the projection of reaching $14.47 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. The expansion during the estimated period is linked to factors such as the implementation of precision medicine, emphasis on disease alteration, recognition and validation of biomarkers, patient-focused drug development, and focus on non-pharmaceutical interventions. Prominent trends throughout this forecast period are expected to include various therapeutic strategies, digital health solutions, renewal medicine, advancements in diagnostic technologies, application of artificial intelligence (AI) in drug discovery, and strategic partnerships and collaborations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Alzheimer’s Drugs Market?

The growth of the Alzheimer’s drugs market is anticipated to be fueled by the escalating incidence of Alzheimer’s disease. This neurological disorder, which progressively worsens, leads to brain atrophy and cell death. Alzheimer’s medication is designed to address issues like memory loss, cognitive and reasoning problems, as well as challenges encountered in daily living. These drugs can not only improve quality of life but also promote independence. Highlighting this trend, a 2024 report from the Alzheimer’s Association, a US-based nonprofit committed to Alzheimer’s care, support and research, pointed out that the number of Americans 65 and older diagnosed with Alzheimer’s dementia went up from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the climbing incidence of Alzheimer’s disease is propelling the growth of the Alzheimer’s drugs market.

Which Key Market Segments Comprise the Alzheimer’s Drugs Market and Drive Its Revenue Growth?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

Which Areas Are Leading Regions in the Alzheimer’s Drugs Market Expansion Across the Globe?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Key Market Trends in the Alzheimer’s Drugs Market Over the Coming Years?

Significant players in the Alzheimer’s drugs market, such as Eli Lilly and Company, are focusing on the development of groundbreaking products like amyloid plaque-targeting therapies. These therapies aim to improve treatment prospects and patient outcomes for Alzheimer’s disease by seeking to minimise or prevent the build-up of amyloid-beta plaques in the brain. In June 2024, the US-based pharmaceutical company, Eli Lilly, received approval from the Food and Drug Administration (FDA), a US Organization dedicated to safeguarding public health, for Kisunla (donanemab-azbt). This product is the first and only treatment targeting amyloid plaque for the early symptomatic stages of Alzheimer’s disease. Kisunla functions by assisting the body in eliminating excessive amyloid plaques, which cause cognitive decline in Alzheimer’s patients, from the brain. It is administered intravenously every four weeks, starting with three doses of 700mg followed by 1400mg for subsequent doses. Kisunla is specifically designed for adults with mild Alzheimer’s dementia and mild cognitive impairment, given that they have confirmed amyloid pathology.

View the full report here:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

How Is the Alzheimer’s Drugs Market Conceptually Defined?

Alzheimer’s drugs refer to drugs that aid in managing memory loss, issues with thinking and reasoning, and daily functioning. These drugs are used to treat Alzheimer’s disease, a brain disorder that causes memory, reasoning, and learning to gradually diminish.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9040

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model